After gains of 5.7% this afternoon, TG Therapeutics shares are now trading at $39.89. Read below for the essential facts about this stock:
-
TG Therapeutics has logged a 160.9% 52 week change, compared to 8.1% for the S&P 500
-
TGTX has an average analyst rating of buy and is -6.87% away from its mean target price of $42.83 per share
-
Its trailing earnings per share (EPS) is $0.15, which brings its trailing Price to Earnings (P/E) ratio to 265.9. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $0.97 and its forward P/E ratio is 41.1
-
The company has a Price to Book (P/B) ratio of 25.84 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 5.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-31413000 and the average free cash flow growth rate is 24.6%
-
TG Therapeutics's revenues have an average growth rate of 333.9% with operating expenses growing at -6.5%. The company's current operating margins stand at 8.8%